Syndivia is committed to enhancing treatment options for patients with solid tumors. We specialize in harnessing the distinctive properties of targeted, site-specific antibody-drug conjugates (ADC), especially those with a DAR of 1 (drug-to-antibody ratio of 1), obtained through our proprietary GeminiMab™ Technology, which provides improved antitumor efficacy.